Abstract. Oral mucosal melanoma (OMM) is a fatal sarcoma of unknown etiology. Histological morphology and genetic events are distinct from those of its cutaneous counterpart. Mutation and up-regulation of c-kit has been identified in OMM which may activate downstream molecules such as RAS and RAF. These molecules are involved in the mitogen-activated protein kinase (MAPK) pathway leading to tremendous cell proliferation and survival. NRAS and BRAF mutation and protein expression have been studied in other melanoma subtypes. The purpose of this study was to determine RAS protein expression and NRAS and BRAF mutation in 18 primary OMM cases using immunohistochemistry and mutation analysis. Results showed that RAS is intensely expressed in both in situ and invasive OMMs. However, NRAS mutation was only observed in 2/15 polymerase chain reaction (PCR) amplified cases both of which were silent mutations. On the other hand, BRAF missense mutations were observed only in 1/15 cases with PCR amplification. NRAS and BRAF mutations were independent from previously reported c-kit mutations. The classical V600E BRAF mutation was not found; instead a novel V600L was observed suggesting that the oncogenic event in OMM is different from that in skin melanoma. The low frequency of NRAS and BRAF mutations indicate that these genes are not common, but probable events in OMM pathogenesis, most likely independent of c-kit mutation.

Introduction

Oral mucosal melanoma (OMM) is a malignant tumor in the oral cavity characterized by adjoining proliferation of atypical melanocytes and alteration of their normal functions. Although OMM is a rare tumor observed in 0.5% of oral malignancies and 0.2-8% of all melanomas, it has an aggressive behavior with poor prognosis (1,2). Precursor lesions have not been clearly elucidated but the onset of atypical melanocytic proliferation may be the earliest indication of its development (1,3). OMM based on histological examination can be classified as in situ, invasive and the combination of both, the latter being the most commonly observed (1,4).

Mitogen-activated protein kinase (MAPK) is the most common pathway described in oncogenic events during the progression of melanoma (5-8). One of the molecules that participate in this signal transduction cascade is RAS encoded by the RAS gene consisting of HRAS, KRAS and NRAS. Another molecule that leads to the activation of MAPK is RAF consisting of ARAF, BRAF and CRAF. Frequent mutations in NRAS and BRAF have been observed in cutaneous melanoma (9-11). The MAPK pathway together with the phosphoinositide 3-kinase cascade (PI3K) can be triggered by activation of c-kit leading to the recruitment of signaling proteins involved in tremendous cell proliferation and survival (12). Mutations in c-kit have been identified in mucosal melanomas rendering c-kit as a promising molecular target (13-15).

NRAS and BRAF mutations have been reported in subsets of mucosal melanomas, but most reports focused on combined mucosal sites (9,16-19). Most reports have claimed that NRAS and BRAF mutations are infrequent, justifying that mucosal melanoma is distinct from its cutaneous counterpart. However, a frequent NRAS mutation was reported in esophageal melanoma (20).

Thus far, therapeutics concerning OMM have not been clearly elucidated. The study aimed to determine RAS protein expression and the incidence of NRAS and BRAF mutations in OMM. The study also compared the NRAS and BRAF mutations to previous investigations on c-kit mutations (13).
Materials and methods

**Tissue samples embedded in paraffin blocks.** A total of 18 cases of primary OMM from the Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, embedded in paraffin blocks were retrospectively analyzed (4). The Institutional Review Board of the University approved the study. The cases were histologically classified according to the Western Society of Teachers in Oral Pathology classification (1). The oral melanotic macule was used as a negative control.

**Immunohistochemistry.** Sections of 3 µm were cut and prepared for immunohistochemistry. Tissue sections were deparaffinized and blocked for endogenous peroxidase using 0.3% hydrogen peroxide in methanol for 30 min and washed with Tris-buffered saline solution. Antigen retrieval was carried out by immersing the slides in citrate buffer (pH 6.0) placed in a pressure cooker for 15 min. The slides were covered with Vectastain Avidin-Biotin complex (mouse, Vector Laboratories, Burlingame, CA, USA) for 15 min followed by 1:20 dilution of a Pan-RAS antibody (OSI Pharmaceuticals, NY, USA) and incubated overnight at 4˚C. Antigenic sites were detected with the ready-to-use 3-amino-ethylcarbazole (AEC) substrate chromogen (DakoCytomation, Carpinteria, CA, USA).

Semi-quantitative analysis of immunohistochemical staining was performed as previously described (13). Briefly, negative (-) means no immunoreaction; focal (±) means <20% melanoma cells are positive with weak staining degree; moderate (+) means 20-50% melanoma cells are positive with strong intensity; and intense (++) means >50% of melanoma cells are positive with strong intensity.

**Mutation analysis.** Genomic DNA extraction was performed on sections from paraffin blocks using the Dexpat kit (Takara Bio, Shiga, Japan) and the High Pure PCR Template kit (Roche Applied Science, Tokyo, Japan) following the manufacturer's protocol. Polymerase chain reaction (PCR) amplified exons 1 and 2 for NRAS and 11 and 15 for BRAF using forward and reverse primers [NC_000007.13 (NRAS) and NC_000001.10 (BRAF), http://www.ncbi.nlm.nih.gov/gene] (Tables I and II). PCR cycling conditions include initial denaturation at 94˚C for 3 min, 45 cycles of denaturation at 94˚C for 30 sec, annealing at 60˚C for NRAS and 54˚C for BRAF for 1 min, extension at 72˚C for 1 min and a final extension at 72˚C for 7 min. PCR products were purified with the Geneclean III kit (QBiogene, USA) or treated with ExoSAP-IT (USB, OH, USA) before sequence-specific PCR. New sets of PCR products were subjected to single strand confirmation polymorphism (SSCP) where aberrant bands were cut, and subjected to PCR followed by ExoSAP-IT treatment and sequence-specific PCR.

Direct sequencing was performed using the Big Dye Terminator v1.1 Cycle Sequencing kit (Applied Biosystems, CA, USA). Sequence reactions were purified with methanol and EDTA precipitation and analyzed on the 3130xl ABI Prism Genetic Analyzer (Applied Biosystems, Hitachi, Japan). Repeat analysis of samples with mutations were carried out using independent DNA for confirmation purpose.

Results of RAS protein expression and NRAS and BRAF mutation analyses were compared to previously reported c-kit mutation and protein expression (13).

**Results**

**Immunohistochemistry.** Normal melanocytes in the oral melanotic macule were negative for the RAS protein (data not shown). On the other hand, tumor cells in OMM intensely expressed RAS. The intense expression was noted both in situ and invasive OMM. A total of 16/18 (89%) cases expressed RAS protein (Fig. 1).

**Mutation analysis.** Frequent aberrant bands were observed in SSCP analysis of NRAS (Fig. 2a, arrows). However, when reactions were sequenced, only 2/15 cases with PCR amplification (13%) had point mutations. For instance, a nucleotide G→A change was observed, but there was no change in the amino acid (Fig. 2b). Numerous aberrant bands were likewise observed in SSCP analysis of BRAF (Fig. 3a, arrows). However, only 1/15 cases...
with PCR amplification (7%) had a point mutation. Incidentally, the nucleotide G→C change altered the amino acid from a valine to a leucine (V600L) (Fig. 3b).

Results of RAS protein expression, and NRAS and BRAF mutations were compared to previously published c-kit results (Table III) (13). It was observed that NRAS and BRAF mutations are independent from c-kit mutations (cases 3 and 12). One NRAS silent mutation coincided with a missense mutation in BRAF wherein no c-kit mutation was found (case 12). Moreover, one RAS protein expression corresponded to a weak c-kit expression without a c-kit mutation (case 3). Furthermore, the case with BRAF and NRAS mutations had only moderate c-kit expression without a c-kit mutation (case 12).

Table III. Comparison of c-kit, NRAS and BRAF mutations in OMM.

<table>
<thead>
<tr>
<th>Case no.</th>
<th>In situ</th>
<th>Invasive</th>
<th>c-Kit</th>
<th>In situ</th>
<th>Invasive</th>
<th>NRAS</th>
<th>BRAF</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>NA</td>
<td>±</td>
<td>WT</td>
<td>NA</td>
<td>++</td>
<td>K166K</td>
<td>WT</td>
</tr>
<tr>
<td>6</td>
<td>+</td>
<td>++</td>
<td>K642E</td>
<td>++</td>
<td>++</td>
<td>WT</td>
<td>WT</td>
</tr>
<tr>
<td>9</td>
<td>±</td>
<td>+</td>
<td>V569G</td>
<td>++</td>
<td>++</td>
<td>WT</td>
<td>WT</td>
</tr>
<tr>
<td>10</td>
<td>NA</td>
<td>-</td>
<td>W557R</td>
<td>NA</td>
<td>++</td>
<td>WT</td>
<td>WT</td>
</tr>
<tr>
<td>12</td>
<td>++</td>
<td>+</td>
<td>WT</td>
<td>++</td>
<td>++</td>
<td>F66F</td>
<td>V600L</td>
</tr>
<tr>
<td>15</td>
<td>NA</td>
<td>++</td>
<td>K642E</td>
<td>NA</td>
<td>++</td>
<td>WT</td>
<td>WT</td>
</tr>
</tbody>
</table>

Successful PCR amplification was obtained in 15 cases. (-), negative; (±), focal; (+), moderate; (++), intense; WT, wild-type; NA, not applicable.

Discussion

With the breakthrough in the field of melanoma research, subsets of melanoma have been described based on anatomic site, sun exposure, histopathologic characteristics and genetic aberrations (1,2,14,21). Investigations aim towards the identification of distinct genetic aberrations in order to target specific molecules responsible for the progression of the tumor. Nevertheless, the complexity behind melanoma oncogenesis is an impediment in improving the prognosis of this fatal type of cancer. Identification of molecular events specific to a subset of melanomas may help develop novel therapeutic agents.
Mutation and up-regulation of c-kit have been studied in mucosal melanomas (14,15,22,23). In particular, activating mutations have been correlated with increased c-kit protein expression (13). A mutated c-kit will lead to phosphorylation without binding of its ligand, stem cell factor, which in turn will activate downstream molecules. MAPK is the best-known pathway activated during the progression of melanoma. Well-known downstream molecules include RAS, which activates BRAF.

A low frequency of NRAS and BRAF mutations was observed in the cases studied. The classical V600E mutation in BRAF was actually not found (27,28). Instead, a novel V600L BRAF mutation was observed, which has not been reported in melanoma or in any other tumors. In spite of the lack in activating mutation in NRAS, RAS protein expression was intense in 89% of the cases. The intense RAS protein expression in both the in situ and invasive phases of OMM may suggest that RAS overexpression is necessary in OMM progression. Activating mutations in c-kit may have induced the intense NRAS protein expression (cases 6, 9, 10 and 15). These events could activate MAPK and PI3K pathways leading to cellular proliferation and survival.

It has been reported that NRAS and BRAF mutations are mutually exclusive (15,19). Interestingly, the case with the BRAF missense mutation had wild-type c-kit (13) suggesting that the c-kit mutation is independent from the BRAF mutation. Other proteins, such as growth factors involved in OMM pathogenesis may activate NRAS or BRAF. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 were expressed in OMM (24). Phosphorylation of VEGFR-2 by its ligand VEGF may activate RAS and RAF signal transduction cascades other than c-kit.

The frequency of intense NRAS protein expression, BRAF and c-kit activating mutations indicates that overlapping of molecular activities may occur in OMM progression posing a major concern in OMM therapy. The variation in genetic aberrations in melanoma as well as the lack of response in molecular therapies strongly supports the notion that OMM may have several putative oncogenic events. This might be another reason why immunotherapy targeting a single molecule was not sufficient. For instance, targeting V600E resulted in an initial response, but acquired resistance developed later (25). In this case, V600E mutation in BRAF may not be the sole genetic aberration in the patients not responding to the treatment. Furthermore, NRAS mutation or up-regulation has been observed in patients who developed acquired resistance to PLX4032 (26). Although NRAS and BRAF mutations are not that frequent in OMM, these molecules are still indispensable when considering immunotherapies in OMM. They may not be the prime factors, but they may be contributors to the oncogenic events in the progression of OMM.

A low frequency of NRAS and BRAF mutation is present in primary OMM. Nevertheless, RAS is intensely expressed in both in situ and invasive OMM. NRAS and BRAF mutations are not common, but probable events in OMM tumorigenesis, most likely independent of c-kit mutation. Overlapping of molecular events may occur in OMM progression, NRAS or BRAF activation may serve as alternative molecular mechanisms in OMM tumorigenesis.

Acknowledgements

The study was supported by grants-in-aid from the Japan Society for the Promotion of Science fellow (no. 22-00130), the Scientific Research (no. 21592326), and the Young Scientists (no. 22791766).

References


